Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis

Morgan, V. A., McGrath, J. J., Jablensky, A., Badcock, J. C., Waterreus, A., Bush, R., Carr, V., Castle, D., Cohen, M., Galletly, C., Harvey, C., Hocking, B., McGorry, P., Neil, A. L., Saw, S., Shah, S., Stain, H. J. and Mackinnon, A. (2013) Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological Medicine, 44 10: 2163-2176. doi:10.1017/s0033291713002973

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ325258OA.pdf Full text (open access) application/pdf 179.56KB 0

Author Morgan, V. A.
McGrath, J. J.
Jablensky, A.
Badcock, J. C.
Waterreus, A.
Bush, R.
Carr, V.
Castle, D.
Cohen, M.
Galletly, C.
Harvey, C.
Hocking, B.
McGorry, P.
Neil, A. L.
Saw, S.
Shah, S.
Stain, H. J.
Mackinnon, A.
Title Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis
Journal name Psychological Medicine   Check publisher's open access policy
ISSN 0033-2917
Publication date 2013-01-01
Year available 2013
Sub-type Article (original research)
DOI 10.1017/s0033291713002973
Open Access Status File (Author Post-print)
Volume 44
Issue 10
Start page 2163
End page 2176
Total pages 14
Place of publication Cambridge, United Kingdom
Publisher Cambridge University Press
Language eng
Formatted abstract
Background: There are insufficient data from nationwide surveys on the prevalence of specific psychotic disorders and associated co-morbidities.

Method: The 2010 Australian national psychosis survey used a two-phase design to draw a representative sample of adults aged 18-64 years with psychotic disorders in contact with public treatment services from an estimated resident population of 1 464 923 adults. This paper is based on data from 1642 participants with an International Classification of Diseases (ICD)-10 psychotic disorder. Its aim is to present estimates of treated prevalence and lifetime morbid risk of psychosis, and to describe the cognitive, physical health and substance use profiles of participants.

The 1-month treated prevalence of psychotic disorders was 3.10 cases per 1000 population aged 18-64 years, not accounting for people solely accessing primary care services; lifetime morbid risk was 3.45 per 1000. Mean premorbid intelligence quotient was approximately 0.5 s.d.s below the population mean; current cognitive ability (measured with a digit symbol coding task) was 1.6 s.d.s below the population mean. For both cognitive tests, higher scores were significantly associated with better independent functioning. The prevalence of the metabolic syndrome was high, affecting 60.8% of participants, and pervasive across diagnostic groups. Of the participants, two-thirds (65.9%) were current smokers, 47.4% were obese and 32.4% were sedentary. Of the participants, half (49.8%) had a lifetime history of alcohol abuse/dependence and 50.8% lifetime cannabis abuse/dependence.

Conclusions: Our findings highlight the need for comprehensive, integrative models of recovery to maximize the potential for good health and quality of life for people with psychotic illness.
Keyword Bipolar disorder
Schizo-affective disorder
Speed of information processing
Substance abuse
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online: 23 December 2013.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Queensland Brain Institute Publications
Official 2014 Collection
School of Public Health Publications
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 47 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 47 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 11 Mar 2014, 21:39:08 EST by Debra McMurtrie on behalf of Queensland Brain Institute